Literature DB >> 19415007

Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy.

Kathy Brown1, Charu Subramony, Warren May, Gail Megason, Hua Liu, Phyllis Bishop, Teresa Walker, Michael J Nowicki.   

Abstract

Hepatic iron overload is a serious complication of chronic transfusion therapy in patients with sickle cell disease (SCD). No firm consensus has been reached with regard to correlation between hepatic iron content (HIC) and variables including age, number of transfusions, and serum iron makers. Also, the role of HIC in determining hepatic injury is not well established. There is scarcity of data on chronically transfused children with SCD and no other confounding liver pathology. We aimed to further explore relationships between these variables in a cohort of children with SCD on chronic transfusion therapy naive to chelation. Liver biopsies obtained before starting chelation therapy from 27 children with sickle cell anemia receiving chronic transfusion therapy were evaluated for histologic scoring and determination of HIC. Average serum ferritin and iron saturation values were determined for 6 months before biopsy. Duration and total volume of transfusion were obtained from the medical records. All children were negative for human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infections. Mean age at biopsy was 10.95+/-3.34 years. Mean duration and total volume of transfusions were 50.0+/-26.6 months and 17.4+/-9.6 L, respectively. Pearson product-moment bivariate correlation coefficients indicated significant correlations between HIC and histologic iron score, serum ferritin, iron saturation, age, and transfusion volume. After adjusting for transfusion volume, a significant correlation was only seen between HIC and transfusion volume. Mean HIC was 21.8+/-10.4 mg/g dry weight, with fibrosis observed in 10 patients and lobular inflammation in 9. HIC was higher in biopsies with fibrosis (28.2+/-3.8 mg/g) than biopsies without fibrosis (17.6+/-18.3 mg/g; P=0.012). HIC did not differ between biopsies with lobular inflammation (25.5+/-4.0 mg/g) and biopsies without inflammation (19.9+/-2.5 mg/g; P=0.22). These findings show that transfusion volume provides more insight on hepatic iron overload than serum iron markers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19415007     DOI: 10.1097/MPH.0b013e3181a1c143

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  15 in total

1.  Retrospective comparison of gradient recalled echo R2* and spin-echo R2 magnetic resonance analysis methods for estimating liver iron content in children and adolescents.

Authors:  Suraj D Serai; Robert J Fleck; Charles T Quinn; Bin Zhang; Daniel J Podberesky
Journal:  Pediatr Radiol       Date:  2015-05-26

2.  Agreement between manual relaxometry and semi-automated scanner-based multi-echo Dixon technique for measuring liver T2* in a pediatric and young adult population.

Authors:  Suraj D Serai; Ethan A Smith; Andrew T Trout; Jonathan R Dillman
Journal:  Pediatr Radiol       Date:  2017-10-23

3.  Iron overload in sickle cell disease.

Authors:  Radha Raghupathy; Deepa Manwani; Jane A Little
Journal:  Adv Hematol       Date:  2010-05-17

Review 4.  Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management.

Authors:  Samir K Ballas; Muge R Kesen; Morton F Goldberg; Gerard A Lutty; Carlton Dampier; Ifeyinwa Osunkwo; Winfred C Wang; Carolyn Hoppe; Ward Hagar; Deepika S Darbari; Punam Malik
Journal:  ScientificWorldJournal       Date:  2012-08-01

5.  Iron metabolism in thalassemia and sickle cell disease.

Authors:  Raffaella Mariani; Paola Trombini; Matteo Pozzi; Alberto Piperno
Journal:  Mediterr J Hematol Infect Dis       Date:  2009-10-27       Impact factor: 2.576

6.  The Role of Nutrition in Sickle Cell Disease.

Authors:  H I Hyacinth; B E Gee; J M Hibbert
Journal:  Nutr Metab Insights       Date:  2010-01-01

7.  Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease.

Authors:  Elliott Vichinsky; Françoise Bernaudin; Gian Luca Forni; Renee Gardner; Kathryn Hassell; Matthew M Heeney; Baba Inusa; Abdullah Kutlar; Peter Lane; Liesl Mathias; John Porter; Cameron Tebbi; Felicia Wilson; Louis Griffel; Wei Deng; Vanessa Giannone; Thomas Coates
Journal:  Br J Haematol       Date:  2011-05-19       Impact factor: 6.998

8.  American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support.

Authors:  Stella T Chou; Mouaz Alsawas; Ross M Fasano; Joshua J Field; Jeanne E Hendrickson; Jo Howard; Michelle Kameka; Janet L Kwiatkowski; France Pirenne; Patricia A Shi; Sean R Stowell; Swee Lay Thein; Connie M Westhoff; Trisha E Wong; Elie A Akl
Journal:  Blood Adv       Date:  2020-01-28

Review 9.  Sickle Hepatopathy.

Authors:  Dibya L Praharaj; Anil C Anand
Journal:  J Clin Exp Hepatol       Date:  2020-08-09

10.  Salivary oxidant/ antioxidant status and hematological parameters in patients with recurrent aphthous stomatitis.

Authors:  Neda Babaee; Hamed Hosseinkazemi; Mahdi Pouramir; Oveis Khakbaz Baboli; Maede Salehi; Fatemeh Khadir; Ali Bijani; Mahsa Mehryari
Journal:  Caspian J Intern Med       Date:  2016
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.